Degarelix Drug Product

Patent No. EP4512389 (titled "Degarelix Drug Product") was filed by Ferring on May 31, 2013. The application was issued on Feb 4, 2026.

UPC Cases New

Latest UPC cases involving this patent.

Case Number	Filing Date	Plaintiff	Proceeding Type
UPC_CFI_0001470/2026	Apr 30, 2026	Ferring, Ferring Center	Infringement

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

Date
Description

Get instant alerts for new documents

Feb 17, 2026
Transmission of the certificate for a European patent pursuant to Rule 74 EPC
Jan 9, 2026
Decision to grant a European patent
Dec 19, 2025
(Electronic) Receipt
Dec 19, 2025
Filing of the translations of the claims
Dec 19, 2025
French translation of claims
Dec 19, 2025
German translation of the claims
Dec 19, 2025
Letter accompanying subsequently filed items
Dec 18, 2025
Annex to the communication about intention to grant a European patent
Dec 18, 2025
Bibliographic data of the European patent application
Dec 18, 2025
Communication about intention to grant a European patent
Dec 18, 2025
Intention to grant (signatures)
Dec 18, 2025
Text intended for grant (clean copy)
Dec 18, 2025
Text intended for grant (version for approval)
Oct 24, 2025
(Electronic) Receipt
Oct 24, 2025
Enquiry as to the processing of the file
Oct 24, 2025
Letter accompanying subsequently filed items
Sep 26, 2025
(Electronic) Receipt
Sep 26, 2025
Amended claims with annotations
Sep 26, 2025
Amended description with annotations
Sep 26, 2025
Annex
Sep 26, 2025
Annex
Sep 26, 2025
Claims
Sep 26, 2025
Description
Sep 26, 2025
Letter accompanying subsequently filed items
Sep 26, 2025
Reply to communication from the Examining Division
Sep 25, 2025
Annex to the communication
Sep 25, 2025
Consultation by telephone/in person (with time limit)
Sep 25, 2025
Result of consultation by telephone/in person
Sep 15, 2025
Examination started
Jul 22, 2025
(Electronic) Receipt
Jul 22, 2025
Letter concerning fees and payments
Jul 10, 2025
(Electronic) Receipt
Jul 10, 2025
Amended claims filed after receipt of (European) search report
Jul 10, 2025
Amended claims with annotations
Jul 10, 2025
Amended description filed after receipt of (European) search report
Jul 10, 2025
Amended description with annotations
Jul 10, 2025
Amendments received before examination
Jul 10, 2025
Letter accompanying subsequently filed items
Jun 24, 2025
Reminder period for payment of examination fee/designation fee and correction of deficiencies in Written Opinion/amendment
May 20, 2025
Refund of fees
May 15, 2025
Communication regarding the transmission of the European search report
May 15, 2025
Document annexed to the Extended European Search Report
May 15, 2025
European search opinion
May 15, 2025
European search report
May 15, 2025
Information on Search Strategy
May 12, 2025
Brief communication to applicant/representative
Apr 30, 2025
(Electronic) Receipt
Apr 30, 2025
Enquiry as to the processing of the file
Apr 30, 2025
Letter accompanying subsequently filed items
Jan 29, 2025
Notification of forthcoming publication
Jan 13, 2025
Priority search results copy provided by EPO
Jan 9, 2025
Abstract
Jan 9, 2025
Acknowledgement of receipt of electronic submission of the request for grant of a European patent
Jan 9, 2025
Claims
Jan 9, 2025
Description
Jan 9, 2025
Designation of inventor
Jan 9, 2025
Drawings
Jan 9, 2025
Request for grant of a European patent
Mar 14, 2015
Priority search results copy provided by EPO
Jan 2, 2014
Priority document (electronically transmitted)

EP4512389

FERRING

Application Number: EP25151066A
Filing Date: May 31, 2013
Status: Granted And Under Opposition; Jan 1, 2026
Publication Date: Feb 4, 2026
External Links: Slate, Register , Google Patents

IP Verse

Degarelix Drug Product

Patent Summary

UPC Cases New

Patent Family

Dossier Documents

EP4512389